Home / CAD / Rivaroxaban approved to prevent CV events in CAD, PAD

Rivaroxaban approved to prevent CV events in CAD, PAD

Janssen announced that the FDA has approved its factor Xa inhibitor rivaroxaban for reduction of risk for major adverse CV events in patients with chronic CAD or peripheral artery disease. Rivaroxaban …
Read Full Story at source (may require registration)